MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Top Cited Papers
- 18 May 2007
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 316 (5827) , 1039-1043
- https://doi.org/10.1126/science.1141478
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)–dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.Keywords
This publication has 20 references indexed in Scilit:
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJournal of Clinical Investigation, 2006
- Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsJournal of Clinical Oncology, 2006
- Inhibition of the Met Receptor in MesotheliomaClinical Cancer Research, 2005
- Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinomaOncogene, 2005
- Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic FeaturesClinical Cancer Research, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001